In a phase I clinical trial (NCT03389815), it was shown to have antitumor activity and a good safety profile in patients with advanced NSCLC who had ALK/ROS1 rearrangements, with an objective response rate (ORR) value of 44.4% (4/9) for screened patients with ROS1 rearrangements treated with iruplinalkib (11). This evidence concerns the gene ALK and non-small cell lung carcinoma.